| Hazard Information | Back Directory | [Uses]
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma[1][5]. | [in vivo]
C-Reactive Protein (CRP) (25 μg; once daily; 7 days; i.v.) can protect mice from pneumococcal infection by activating complement[1].
C-Reactive Protein (CRP) (20 mg/kg; once daily; 3 days; i.p.) can induce superoxide anion release and tissue factor activity in rat macrophages[2]. | Animal Model: | A murine model of pneumococcal infection[1]. | | Dosage: | 25 μg | | Administration: | Intravenous injection (i.v.); once daily; 7 days | | Result: | Activated complement in mouse serum. |
| Animal Model: | Male hooded Wistar rats (weighing 125-150 g)[2]. | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (i.p.); once daily; 3 days | | Result: | Upregulated PKC, NADPH oxidase, ERK, and JNK phosphorylation. |
| [References]
[1] Singh SK, et al. Complement Activation by C-Reactive Protein Is Critical for Protection of Mice Against Pneumococcal Infection. Front Immunol. 2020 Aug 13;11:1812. DOI:10.3389/fimmu.2020.01812
[2] Devaraj S, et al. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis. 2009 Mar;203(1):67-74. DOI:10.1016/j.atherosclerosis.2008.05.060
[3] Chen JY, et al. C-reactive protein derived from perivascular adipose tissue accelerates injury-induced neointimal hyperplasia. J Transl Med. 2020 Feb 11;18(1):68. DOI:10.1186/s12967-020-02226-x
[4] Tang Y, et al. C-reactive protein promotes acute kidney injury by impairing G1/S-dependent tubular epithelium cell regeneration. Clin Sci (Lond). 2014 May;126(9):645-59. DOI:10.1042/CS20130471
[5] Yan X, et al. C-reactive protein promotes tongue squamous cell carcinoma chemoresistance by inhibiting the activation of caspase-3/9 via the CD64/AKT/mTOR pathway. Hum Cell. 2021 Sep;34(5):1424-1433. DOI:10.1007/s13577-021-00555-7
[6] Ansar W, et al. C-reactive protein and the biology of disease. Immunol Res. 2013 May;56(1):131-42. DOI:10.1007/s12026-013-8384-0 |
|
|